http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2738167-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79ae6dd5bafbd2dd69035367385d754c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2020-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc682e766a68a6acc286e35eedc9a171 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95aab8d45e7809877032bba26840f992 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dfcace8009131eef296d32868dcc275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea1f8ce33625182d8ab0ad8ecf0459b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_676a8c0c3d78bbf6dc300acb899eff1e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fb21ee00e225b9fe549ccfd89ed2757 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7c81abf028a1396052662cb1b9a689c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_594b2b94970e29f246835dae09696feb |
| publicationDate | 2020-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2738167-C1 |
| titleOfInvention | Method for determining the effectiveness of chemotherapy with platinum preparations in iii-iv stage ovarian cancer |
| abstract | FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for early detection of efficacy of antitumour treatment of ovarian cancer III-IV stage. Method involves complete or optimal/suboptimal cytoreductive volume following 3 courses of non-adjuvant polychemotherapy with platinum preparations for patients with ovarian cancer III-IV stage. Tissue fragment of the primary malignant tumor, as well as the metatastically involved omentum and peritoneum in volume of 100-120 mg are sampled, tissue 10% homogenate is prepared in a buffered physiological saline of pH 7.4, protein HE-4 level is determined in the samples. If its value is 170.0-186.6 pmol/l in primary malignant tissue, in tissue of metastatic diseased omentum 153.1-175.5 pmol/l and in tissue of metastatically involved peritoneum 128.7-149.7 pmol/l effectiveness of postoperative chemotherapy with platinum preparations used in neoadjuvant mode is predicted. If the value in the primary malignant tissue within range of 1667.6-1976.2 pmol/l, in tissue of metastatically involved greater omentum 1109.6-1307.0 pmol/l and in tissue of metastatically involved peritoneum 1429.2-1693.4 pmol/l absence of efficacy of postoperative chemotherapy with platinum preparations used in neoadjuvant mode is predicted.EFFECT: use of the invention enables assessing the efficacy of the neoadjuvant polychemotherapy with platinum preparations in ovarian carcinoma by the levels of the tumor markerHe-4 in the tissues of primary and metastatic tumors to predict the effectiveness of subsequent courses of platinum-containing chemotherapy.1 cl, 4 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2800817-C1 |
| priorityDate | 2020-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 78.